AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447

1 week ago 8

Jeff Lewis

Sun, April 12, 2026 astatine 1:46 PM CDT 2 min read

AgomAb Therapeutics NV (NASDAQ:AGMB) is 1 of the

7 Best Strong Buy European Stocks to Invest In. On March 26, 2026, AgomAb Therapeutics NV (NASDAQ:AGMB) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,577,230 covering the creation of substance for AGMB-447. The institution said AGMB-447 is an investigational inhaled, lung-restricted tiny molecule inhibitor of ALK5 presently successful a Phase 1b survey for idiopathic pulmonary fibrosis, with the patent providing extortion successful the U.S. done astatine slightest 2041, excluding imaginable extensions.

Earlier successful March, Leerink expert Thomas J. Smith initiated sum connected Agomab with an Outperform standing and a $36 terms target. The expert cited upcoming information readouts, expanding involvement successful anti-fibrotic and inflammatory bowel illness treatments, and capable superior to scope cardinal milestones, describing 2026 arsenic a milestone-rich twelvemonth with imaginable upside.

AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447

Similarly, JPMorgan initiated sum connected Agomab with an Overweight standing and a $32 terms target. JPMorgan highlighted ontunisertib, an oral gut-restricted ALK5 inhibitor targeting fibrostenosing Crohn’s disease, noting Phase 2a information showed “encouraging” efficacy signals crossed aggregate endpoints on with a cleanable information profile.

AgomAb Therapeutics NV (NASDAQ:AGMB) develops therapies targeting immunology and chronic fibrotic diseases.

While we admit the imaginable of AGMB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article